270 related articles for article (PubMed ID: 23695213)
1. Focal adhesion kinase is required for IGF-I-mediated growth of skeletal muscle cells via a TSC2/mTOR/S6K1-associated pathway.
Crossland H; Kazi AA; Lang CH; Timmons JA; Pierre P; Wilkinson DJ; Smith K; Szewczyk NJ; Atherton PJ
Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E183-93. PubMed ID: 23695213
[TBL] [Abstract][Full Text] [Related]
2. Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of s6 kinase activation and cell growth.
Gan B; Yoo Y; Guan JL
J Biol Chem; 2006 Dec; 281(49):37321-9. PubMed ID: 17043358
[TBL] [Abstract][Full Text] [Related]
3. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
Miyazaki M; McCarthy JJ; Esser KA
FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
[TBL] [Abstract][Full Text] [Related]
4. Ataxia telangiectasia mutated impacts insulin-like growth factor 1 signalling in skeletal muscle.
Ching JK; Luebbert SH; Collins RL; Zhang Z; Marupudi N; Banerjee S; Hurd RD; Ralston L; Fisher JS
Exp Physiol; 2013 Feb; 98(2):526-35. PubMed ID: 22941977
[TBL] [Abstract][Full Text] [Related]
5. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.
Marin TM; Clemente CF; Santos AM; Picardi PK; Pascoal VD; Lopes-Cendes I; Saad MJ; Franchini KG
Circ Res; 2008 Oct; 103(8):813-24. PubMed ID: 18757826
[TBL] [Abstract][Full Text] [Related]
6. Skeletal myocyte hypertrophy requires mTOR kinase activity and S6K1.
Park IH; Erbay E; Nuzzi P; Chen J
Exp Cell Res; 2005 Sep; 309(1):211-9. PubMed ID: 15963500
[TBL] [Abstract][Full Text] [Related]
7. AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation.
Ning J; Clemmons DR
Mol Endocrinol; 2010 Jun; 24(6):1218-29. PubMed ID: 20363874
[TBL] [Abstract][Full Text] [Related]
8. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses.
Smith EM; Finn SG; Tee AR; Browne GJ; Proud CG
J Biol Chem; 2005 May; 280(19):18717-27. PubMed ID: 15772076
[TBL] [Abstract][Full Text] [Related]
9. A dynamic ribosomal biogenesis response is not required for IGF-1-mediated hypertrophy of human primary myotubes.
Crossland H; Timmons JA; Atherton PJ
FASEB J; 2017 Dec; 31(12):5196-5207. PubMed ID: 28774889
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins.
Liu L; Chen L; Chung J; Huang S
Oncogene; 2008 Aug; 27(37):4998-5010. PubMed ID: 18504440
[TBL] [Abstract][Full Text] [Related]
11. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
12. Endotoxin disrupts the leucine-signaling pathway involving phosphorylation of mTOR, 4E-BP1, and S6K1 in skeletal muscle.
Lang CH; Frost RA
J Cell Physiol; 2005 Apr; 203(1):144-55. PubMed ID: 15389631
[TBL] [Abstract][Full Text] [Related]
13. Identification of FIP200 interaction with the TSC1-TSC2 complex and its role in regulation of cell size control.
Gan B; Melkoumian ZK; Wu X; Guan KL; Guan JL
J Cell Biol; 2005 Aug; 170(3):379-89. PubMed ID: 16043512
[TBL] [Abstract][Full Text] [Related]
14. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
[TBL] [Abstract][Full Text] [Related]
15. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
16. Identification of mechanically regulated phosphorylation sites on tuberin (TSC2) that control mechanistic target of rapamycin (mTOR) signaling.
Jacobs BL; McNally RM; Kim KJ; Blanco R; Privett RE; You JS; Hornberger TA
J Biol Chem; 2017 Apr; 292(17):6987-6997. PubMed ID: 28289099
[TBL] [Abstract][Full Text] [Related]
17. c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation.
Ravitz MJ; Chen L; Lynch M; Schmidt EV
Cancer Res; 2007 Dec; 67(23):11209-17. PubMed ID: 18056446
[TBL] [Abstract][Full Text] [Related]
18. Early dietary restriction in rats alters skeletal muscle tuberous sclerosis complex, ribosomal s6 and mitogen-activated protein kinase.
Calkins KL; Thamotharan S; Dai Y; Shin BC; Kalhan SC; Devaskar SU
Nutr Res; 2018 Jun; 54():93-104. PubMed ID: 29685622
[TBL] [Abstract][Full Text] [Related]
19. Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2).
Rolfe M; McLeod LE; Pratt PF; Proud CG
Biochem J; 2005 Jun; 388(Pt 3):973-84. PubMed ID: 15757502
[TBL] [Abstract][Full Text] [Related]
20. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size.
Trendelenburg AU; Meyer A; Rohner D; Boyle J; Hatakeyama S; Glass DJ
Am J Physiol Cell Physiol; 2009 Jun; 296(6):C1258-70. PubMed ID: 19357233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
